New 52 Week Low Today

BriaCell Therapeutics Equity Warrant Exp 26th Feb 2026 BCTXW:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:35 PM EDT
0.7877quote price arrow up+0.0577 (+7.9041%)
Volume
25,519
52 week range
0.59 - 3.30
Loading...
  • Open0.6638
  • Day High0.85
  • Day Low0.59
  • Prev Close0.73
  • 52 Week High3.30
  • 52 Week High Date08/18/23
  • 52 Week Low0.59
  • 52 Week Low Date05/16/24

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.6638
  • Day High0.85
  • Day Low0.59
  • Prev Close0.73
  • 52 Week High3.30
  • 52 Week High Date08/18/23
  • 52 Week Low0.59
  • 52 Week Low Date05/16/24
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On BriaCell Therapeutics Equity Warrant Exp 26th Feb 2026

 

Profile

MORE
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The...
Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
William Williams M.D.
President, Chief Executive Officer, Director
Gadi Levin
Chief Financial Officer, Corporate Secretary
Address
3rd Floor
Bellevue Centre,, 235-15th Str
West Vancouver, BC
V7T 2X1
Canada